

The [Spin to Save Kids!](#) Challenge, organized by the [Institute for Advanced Clinical Trials for Children](#) (I-ACT) is the inaugural nationwide challenge that takes place through March 2023. Local communities, associations and organization across the country will gather and participate in various challenges—spinning balls, tops, tire swings, and other creative ways to call attention to the disparities and inequities in children’s pharmaceutical development and approval.

Register TODAY at <http://www.spinchallenge.org>

I-ACT is the nation’s leading organization exclusively committed to advancing and accelerating Children’s Clinical Trials. On average, it takes 15 years to complete a pediatric drug development program and nine years from adult approval for a pediatric label to be made. Because innovative drug development in pediatrics is slow and inadequate, more than 50% of the drugs used in children and 90% in neonates are prescribed off-label and without sufficient data to identify the correct dose and potential adverse effects. I-ACT strives to shorten the time it takes to bring innovative medicines and devices to them.

By taking the Spin Challenge! you will help accelerate the development of life-saving vaccines, medicines, and medical devices for the nation’s children.

Your donation will help I-ACT protect children; challenge pediatricians, bio-pharma companies, and clinical research organizations; and encourage others to help advance Children’s Clinical Trials.

ABOUT I-ACT

I-ACT for Children is a 501(c)(3) nonprofit organization dedicated to ensuring every child with a medical need receives timely access to the best therapies and committed to advocating on behalf of children with the same level of urgency afforded to adults.

CONTACT FOR FURTHER INFORMATION AND TO HELP WITH REGISTRATION

Jill Arnstein

advancement@iactc.org

818.667.2204



Office: 9211 Corporate Blvd, Suite 260 Rockville, MD 20850

Phone: 301.605.7571

www.iactc.org

This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error, please notify the sender immediately and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.